Premium
Helix BioPharma Corp (HBP)
TSX
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
RICHMOND HILL, Ontario, July 30, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer...
RICHMOND HILL, Ontario, July 13, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, June 26, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in...
NEW YORK, June 22, 2020 (GLOBE NEWSWIRE) -- Proactive, the digital financial news organization, will be showcasing four rising stars of the life sciences industry with its first North American...
RICHMOND HILL, Ontario, June 22, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, June 11, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, May 14, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, April 02, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, March 16, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer...
RICHMOND HILL, Ontario, March 12, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.03 | -3 | 1 | 1 | 0.87 | 5943 | 0.9966145 | CS |
| 4 | 0.22 | 29.3333333333 | 0.75 | 1.06 | 0.71 | 8791 | 0.96030357 | CS |
| 12 | -0.09 | -8.49056603774 | 1.06 | 1.34 | 0.5 | 11818 | 0.83876781 | CS |
| 26 | -0.18 | -15.652173913 | 1.15 | 1.35 | 0.5 | 8795 | 0.96675606 | CS |
| 52 | -0.08 | -7.61904761905 | 1.05 | 1.35 | 0.5 | 9228 | 0.96770838 | CS |
| 156 | -0.78 | -44.5714285714 | 1.75 | 1.875 | 0.5 | 13574 | 1.10854897 | CS |
| 260 | -6.53 | -87.0666666667 | 7.5 | 10.05 | 0.5 | 17225 | 2.21853015 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
